Research
Energy balance
Once-weekly subcutaneous semaglutide (2.4 mg) resulted in a mean body weight change of -16.0% compared to -5.7% for placebo at week 68.
Semaglutide can be an effective adjunct treatment for weight management in adults with overweight or obesity.
StrongSupportsmedium confidence
At week 68, the estimated mean body weight change from baseline was -16.0% for semaglutide vs -5.7% for placebo.
Why this rating
Based on a randomized, double-blind, parallel-group, phase 3a study design.
Source
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
Thomas A. Wadden et al. · JAMA · 2021
DOI 10.1001/jama.2021.1831
rct · n=611Cited 983×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →